Search Results
Results found for "Omass Therapeutics"
- Celtarys Research | Dr. GPCR Ecosystem
Biology: The Role of Fluorescent Ligands in GPCR Research GPCRs are one of the most important families of therapeutic Celtarys’ cutting-edge fluorescent ligand technology and accelerate the development of GPCR-targeted therapeutics accelerate the adoption of our chemical tools and foster collaborations that turn receptor biology into therapeutic
- Signals, pH, and Discovery : Cracking GPCR Mysteries with Dr. Ian Chronis | Dr. GPCR Ecosystem
Yamina underscores the therapeutic potential of GPR65, especially in the context of cancer immunotherapy , and how understanding receptor activity in acidic micro environments could unlock new therapeutic strategies
- Elva Zhao: G Protein Regulation and Biased Signaling at the GLP-1 Receptor | Dr. GPCR Ecosystem
the most clinically validated targets in metabolic disease - yet the signaling logic separating the therapeutic pharmacologists have not yet addressed actually shape signaling output at one of the field's most important therapeutic receptor Transducer coupling as the missing mechanistic layer in GLP-1 receptor pharmacology The expanding therapeutic modulate the functional output at this receptor, and whether that regulatory layer contributes to the therapeutic
- Dr. Lauren M. Slosky | Dr. GPCR Ecosystem
protein-coupled receptors (GPCRs) regulate motivated behavior and how these receptors can be targeted for therapeutic distinct signaling pathways with their physiological effects and may serve as the basis for more selective therapeutics
- How Lipid Rafts Organize GPCR Signaling | Dr. GPCR Ecosystem
Keyvan Sedaghat discussing how GPCR function is shaped by lipid raft compartmentalization, the expanding therapeutic efficacy and diagnostic innovation What the functional diversity of bitter taste receptors means for novel therapeutic
- Fiona Marshall: Three Decades Inside GPCR Drug Discovery | Dr. GPCR Ecosystem
thermostabilization strategy finally made GPCR structures routine, the insight that seeded Heptares Therapeutics She co-founded Heptares Therapeutics and served as Chief Scientific Officer for twelve years, through As a co-founder of Heptares Therapeutics , now called Sosei Heptares , a GPCR-focused drug discovery
- Fluorescent Probes for GLP-1R and GIPR Imaging: From Cell Assays to In Vivo Systems | Dr. GPCR Ecosystem
His work carries direct translational relevance to diabetes and obesity therapeutics. opportunities for scientists and biotech leaders working across pharmacology, translational research, and therapeutic
- Receptor Signaling Bias: A Valuable and Accessible Property of New Drug Candidates | Dr. GPCR Ecosystem
development, with 25+ years of expertise and validated cell-based assays spanning basic research through therapeutic opportunities for scientists and biotech leaders working across pharmacology, translational research, and therapeutic
- Dr. Michael Feigin | Dr. GPCR Ecosystem
Michael Feigin is an Associate Professor in the Department of Pharmacology and Therapeutics, and Director of Graduate Studies of Experimental Therapeutics at Roswell Park Comprehensive Cancer Center in Buffalo disrupting histone processing on rapidly proliferating cells, such as cancer cells, and suggested a therapeutic
- Irfan Dhanidina, Dr. Kathleen Caron and Dr. Lauren Slosky | Dr. GPCR Ecosystem
protein-coupled receptors (GPCRs) regulate motivated behavior and how these receptors can be targeted for therapeutic distinct signaling pathways with their physiological effects and may serve as the basis for more selective therapeutics
- Exploring Career Paths in GPCR Research with Dr. Jacek Mokrosiński | Dr. GPCR Ecosystem
Yamina will schedule a future talk with Jacek about GPCRs as therapeutic modalities. The discussion revealed their interest in GPCRs as therapeutic modalities and possible future collaborations
- Yao Lu (Jackie) | Dr. GPCR Ecosystem
molecular explanation of small molecules for their pre-clinical efficacy and to support the design of novel therapeutics
- Tanishka S. Saraf | Dr. GPCR Ecosystem
Saraf " My research focuses on evaluating and targeting serotonin 1A receptors for therapeutic outcomes
- Dr. Jean-Philippe Pin | Dr. GPCR Ecosystem
biosensors, cryo-EM, photoswitchable ligands, and nanobodies as pharmacological tools and potential therapeutic
- Fresh, Fresh, GPCR News ❇ Feb 17 - 23, 2025 | Dr. GPCR Ecosystem
Terry Kenakin’s unique course, Development of GPCR Ligands as Therapeutic Drugs , and gain essential signaling and drug discovery Symposium & Workshop - Brazil NEW April 1 - 3, 2025 | 2nd Peptide-Based Therapeutics Summit - USA April 2 - 3, 2025 | New therapeutic modalities: Transforming receptor pharmacology - UK Australia GPCR Jobs NEW Open Postdoctoral position - Stanford University Structural Biologist - Confo Therapeutics Pharmacologist - Schrödinger Scientist - Biology - Superluminal Medicines Scientist I Cell Biology - Tectonic Therapeutic
- The Role of Quantitative Sciences in GPCRs with Dr. Nagarajan Vaidehi | Dr. GPCR Ecosystem
She has advanced the use of computational methods to meet the challenges of designing therapeutics with
- Yamina's Corner | Dr. GPCR Ecosystem
Clear Platform Assessment: Gain rapid, independent insight into GPCR platform risks and true therapeutic Abishek Iyer, CEO Ashta Therapeutics Before working with Yamina, we had solid internal momentum but needed
- Dr. Andrew Tobin | Dr. GPCR Ecosystem
vehicle by which Andrew is translating fundamental findings to commercial products is Keltic Pharma Therapeutics
- Dr. Nicola J. Smith | Dr. GPCR Ecosystem
orphan GPCRs from ‘locked’, inaccessible receptors to well-characterized and understood ‘unlocked’ therapeutic
- Dr. Adriano Marchese | Dr. GPCR Ecosystem
The ultimate goal of Adriano’s research is to target novel aspects of GPCR signaling for therapeutic
- Terry Hebert: How Cellular Background and Localization Influence GPCR Function | Dr. GPCR Ecosystem
Terry Hebert is a Professor of Pharmacology and Therapeutics at McGill University. The goal is to test therapeutic strategies targeting the AT1R, alpha-adrenergic, and beta-adrenergic
- Dr. Stephen Ferguson | Dr. GPCR Ecosystem
Brian Collier in the Department of Pharmacology and Therapeutics at McGill University (1994).
- Dr. Stephen Ferguson | Dr. GPCR Ecosystem
Brian Collier in the Department of Pharmacology and Therapeutics at McGill University (1994).
- Dr. Timo De Groof | Dr. GPCR Ecosystem
nanobodies as research tools, to investigate different GPCR conformations, while also focusing on their therapeutic
- Brian Arey - Part 2: GPCR Drug Discovery and the Science Nobody Publishes | Dr. GPCR Ecosystem
GPR56 as a mechanical sensor and his sustained case for the KLF2 signaling pathway as a GPCR-linked therapeutic His recently published book on signaling bias, Biased Signaling in Physiology, Pharmacology, and Therapeutics
- Kathryn Livingston: Allosteric Opioid Modulators and Receptor Signaling Beyond the Membrane | Dr. GPCR Ecosystem
Themes of the Conversation Allosteric modulation of opioid receptors - mechanism, selectivity, and therapeutic The therapeutic logic is that decoupling from the orthosteric site might preserve pain relief while altering
- Sam Hoare: Receptor Residence Time and GPCR Data Analysis | Dr. GPCR Ecosystem
company supporting pharmaceutical, life science, and academic scientists in the development of new therapeutics analysis of drug action and is known for applying binding kinetics to the development of effective therapeutics
- Pfleger: NanoBRET, Receptor Complexes, and the Translation of GPCR Pharmacology | Dr. GPCR Ecosystem
GPCR field, and serves as Deputy Director of the Australian Research Council Centre for Personalised Therapeutics Institute of Medical Research, Deputy Director of the Australian Research Council Centre for Personalised Therapeutics
- Dr. John Streicher: Reorganizing Opioid Signaling Beyond the Receptor | Dr. GPCR Ecosystem
Current lines of work include isoform-selective HSP90 inhibition as a strategy for widening the opioid therapeutic This is not a quirk — it is the central clue the lab has built a therapeutic strategy around.
- Your GPCR Order Has Arrived! ❇ Feb 10 - 16, 2025 | Dr. GPCR Ecosystem
. 🗓️ Upcoming 4-Week Course: Development of GPCR Ligands as Therapeutic Drugs starting March 20 – April biotechs public Aikium's AI-Driven mRNA Engine Looks to Address Undruggable Disordered Proteins Tectonic Therapeutic - 21, 2025 | 2nd GPCR signaling and drug discovery Symposium & Workshop NEW April 2 - 3, 2025 | New therapeutic PhD Position GPCR Molecular Pharmacologist Scientist - Biology Scientist I Cell Biology - Tectonic Therapeutic




























